Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Marie Skłodowska-Curie Action · Running

IDPro Intrinsically disordered proteins in health and disease: mechanisms, molecular context and opportunities for drug discovery

Coordinator
Uppsala Universitet, Sweden
Runs
1 September 2023 to 31 August 2027
Status
Running
EU funding
€2.7m
Total cost
—
Partners
14 organisations in 7 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101119633

What the project is doing

In the project's own words, from its summary on CORDIS.

Proteins dictate virtually all cellular processes. To do so, precise 3D-structures that fit to their binding partners are exploited. However, up to 40% of the human proteome exist in disordered, dynamic ensembles of states mandatory for function. These so-called intrinsically disordered protein and regions (IDPs) play crucial roles in most aspects of life. They mediate tens of thousands of protein-protein interactions involved in cell signaling, scaffolding, transcription, membrane-less organelles and more.

While the pivotal role of IDPs in biology is recognized, most of their functions remains unexplored. The time is now ripe for the next frontier, decomposing protein-protein interactions involving IDPs on a large scale. Importantly, IDPs are emerging drug targets for treating complex diseases: cancer, neurodegenerative disorders, metabolic syndromes and viral diseases, afflicting an ageing European population. The evolving field demands a new generation of experts to take the lead in developing different types of drugs targeting IDP interactions.

This MSCA DN project aims to educate ten doctoral students within this evolving field by tackling outstanding questions. In particular, we will delineate the role of context in interactions involving IDPs, including flanking regions, folded domains, disease-related mutations, and aberrant cellular signaling and also design peptide-based ligands based on disordered regions that can potentially be further developed into drugs or molecular probes.

A team of 14 established scientists from seven academic institutes and five companies, with excellent experience in supervision and cutting edge knowledge on IDPs and experimental and computational techniques will form IDPro. IDPro constitutes an exceptional network where the PhD students can mature and obtain scientific excellence in academic as well as non-academic settings. IDPro will strengthen the future academic and biotech labor force of the European union.

Topics

Who is involved

OrganisationCityCountryRole
Uppsala UniversitetUppsalaSwedenCoordinator
Universitat ZurichZurichSwitzerlandAssociatedpartner
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyAssociatedpartner
Systasy Bioscience GmbHPlaneggGermanyParticipant
Kobenhavns UniversitetKobenhavnDenmarkParticipant
Novo Nordisk A/sBagsvaerdDenmarkAssociatedpartner
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Institut Servier D'innovation TherapeutiqueGif-Sur-YvetteFranceAssociatedpartner
Universite Grenoble AlpesGrenobleFranceAssociatedpartner
Eotvos Lorand TudomanyegyetemBudapestHungaryParticipant
Universita Degli Studi Di Napoli Federico IiNapoliItalyParticipant
Universita Degli Studi Di Roma La SapienzaRomaItalyParticipant
Astrazeneca ABSodertaeljeSwedenAssociatedpartner
Cytiva Testa Center ABUppsalaSwedenAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI